Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...
The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...
Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...
Zacks Investment Research on MSN4d
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyShares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).
Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...
The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback